Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children
Public ClinicalTrials.gov record NCT00383123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Single-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix® (GSK Biologicals') Compared With Fluzone® (Aventis Pasteur/Sanofi) Administered Intramuscularly in Children (6 Months and Older)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare two influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Study identification
- NCT ID
- NCT00383123
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 3,327 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 6 Months to 17 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2006 (Type not available)
- Primary completion
- Oct 1, 2007 (Actual)
- Completion
- Oct 19, 2007 (Actual)
- Last update posted
- Jun 8, 2018
2006 – 2007
United States locations
- U.S. sites
- 40
- U.S. states
- 13
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Antioch | California | 94509 | — |
| GSK Investigational Site | Fairfield | California | 94533 | — |
| GSK Investigational Site | Fresno | California | 93710 | — |
| GSK Investigational Site | Pleasanton | California | 94588 | — |
| GSK Investigational Site | Redwood City | California | 94063 | — |
| GSK Investigational Site | Richmond | California | 94801 | — |
| GSK Investigational Site | Rolling Hills Estates | California | 90274 | — |
| GSK Investigational Site | Sacramento | California | 95815 | — |
| GSK Investigational Site | San Francisco | California | 94102 | — |
| GSK Investigational Site | San Francisco | California | 94115 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | Santa Rosa | California | 95403 | — |
| GSK Investigational Site | Vacaville | California | 95688 | — |
| GSK Investigational Site | Vallejo | California | 94589 | — |
| GSK Investigational Site | Walnut Creek | California | 94596 | — |
| GSK Investigational Site | Englewood | Colorado | 80112 | — |
| GSK Investigational Site | Lakewood | Colorado | 80401 | — |
| GSK Investigational Site | Tifton | Georgia | 31794 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Lexington | Kentucky | 40509 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Omaha | Nebraska | 68134 | — |
| GSK Investigational Site | Whitehouse Station | New Jersey | 08889 | — |
| GSK Investigational Site | Fishkill | New York | 12524 | — |
| GSK Investigational Site | Hopewell Junction | New York | 12533 | — |
| GSK Investigational Site | Poughkeepsie | New York | 12603 | — |
| GSK Investigational Site | Rochester | New York | 14609 | — |
| GSK Investigational Site | Rochester | New York | 14620 | — |
| GSK Investigational Site | Cary | North Carolina | 27518 | — |
| GSK Investigational Site | Sylva | North Carolina | 28779 | — |
| GSK Investigational Site | Cleveland | Ohio | 44118 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| GSK Investigational Site | Uniontown | Pennsylvania | 15401 | — |
| GSK Investigational Site | Austin | Texas | 78728 | — |
| GSK Investigational Site | Fort Worth | Texas | 76135 | — |
| GSK Investigational Site | San Angelo | Texas | 76904 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84121 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
| GSK Investigational Site | West Jordan | Utah | 84084 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00383123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2018 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00383123 live on ClinicalTrials.gov.